PSMA-PET may be the way to go to optimize accurate initial staging for prostate cancer, but how does it fare for biochemical recurrences? The phase 3 CONDOR trial enrolled over 200 men with biochemical recurrences of prostate cancer but without visible disease on imaging. They all received PSMA-PET, and 69% of these detected radiographic disease with 64% changing treatment plans because of it. TBL: PSMA-PET for initially radiographic elusive biochemically recurrent prostate cancer has a huge impact on determining appropriate management. | Morris, ASCO 2020


Popular Posts